Document is current
Any future updates will be listed below
-
Authors
Rodríguez-Otero, Paula https://orcid.org/0000-0001-5236-7785
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Kouwenhoven, Mathilde https://orcid.org/0000-0001-5252-4365
Schecter, Jordan M.
Lendvai, Nikoletta
De Braganca, Kevin C. https://orcid.org/0000-0001-7354-1244
Slaughter, Ana
Lonardi, Carolina
Vlummens, Philip
Varsos, Helen
Corsale, Christina
Madduri, Deepu
Zhao, Hao
Li, Katherine
Lee, Erin https://orcid.org/0000-0002-8728-7627
Marquez, Loreta
Zhao, Man
Yeh, Tzu-min
Chen, Diana
Plaks, Vicki
Montes de Oca, Rocio https://orcid.org/0000-0002-6576-7240
Florendo, Erika
Patel, Nitin
Akram, Muhammad
Koneru, Mythili
Santomasso, Bianca D. https://orcid.org/0000-0001-9423-4059
Gállego Perez-Larraya, Jaime https://orcid.org/0000-0003-2969-0116
van de Donk, Niels WCJ https://orcid.org/0000-0002-7445-2603
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 2 April 2025
Revised: 17 October 2025
Accepted: 11 November 2025
First Online: 26 November 2025
Competing interests
: Paula Rodríguez-Otero Consulting or advisory role: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Oncopeptides, Pfizer, Roche, Sanofi. Travel, accommodations, and expenses: Pfizer. Honoraria: Amgen, Bristol Myers Squibb, GlaxoSmithKline, H3 Biomedicine, Johnson & Johnson, Regeneron, Sanofi. Surbhi Sidana Consulting or advisory role: AbbVie, Bristol Myers Squibb, Johnson & Johnson, Kite, Legend Biotech USA Inc., Magenta Therapeutics, Oncopeptides, Pfizer, Regeneron, Sanofi, Takeda. Research funding: Allogene, Bristol Myers Squibb, Johnson & Johnson, Magenta Therapeutics, Novartis. Mathilde Kouwenhoven No conflicts of interest. Jordan M. Schecter Employment and patent and royalty interests: Johnson & Johnson Equity: Johnson & Johnson. Nikoletta Lendvai Employment: Johnson & Johnson Stock options: Johnson & Johnson. Kevin C. De Braganca Employment: Johnson & Johnson. Ana Slaughter Employment: Johnson & Johnson Equity: a privately held company Stock options: a privately held company. Carolina Lonardi Employment: Johnson & Johnson. Philip Vlummens Employment: Johnson & Johnson (at the time the work was performed). Stock options: Johnson & Johnson. Helen Varsos Employment: Johnson & Johnson. Equity: Johnson & Johnson. Christina Corsale Employment: Johnson & Johnson Equity: a publicly traded company. Deepu Madduri Employment: Johnson & Johnson. Hao Zhao Employment: Johnson & Johnson. Katherine Li Employment: Johnson & Johnson Equity: Johnson & Johnson. Erin Lee Employment: Johnson & Johnson Equity: Johnson & Johnson. Loreta Marquez Employment: Johnson & Johnson Equity: Johnson & Johnson Divested equity in the past 24 months: Johnson & Johnson. Man Zhao Employment: IQVIA. Tzu-min Yeh Employment: Johnson & Johnson Equity: Johnson & Johnson Stock options: Johnson & Johnson. Diana Chen Employment: Johnson & Johnson Stock options and other ownership interests: Johnson & Johnson. Vicki Plaks Employment: Johnson & Johnson Equity: Johnson & Johnson. Rocio Montes de Oca Employment: Johnson & Johnson. Stock options and other ownership interests: Johnson & Johnson. Erika Florendo Employment: Legend Biotech USA Inc. Equity: a publicly traded company. Nitin Patel Employment: Legend Biotech USA Inc. Equity: Legend Biotech USA Inc. Muhammad Akram Employment: Legend Biotech USA Inc. Equity: a publicly traded company. Mythili Koneru Employment: Legend Biotech USA Inc. Stock options and other ownership interests: Legend Biotech USA Inc. Bianca D. Santomasso Consulting or advisory role: Bristol Myers Squibb/Celgene, Gilead Sciences, IN8Bio, Johnson & Johnson. Jaime Gállego Perez-Larraya Consulting or advisory role and honoraria: GlaxoSmithKline, Johnson & Johnson. Travel, accommodations, and expenses: Janssen. Niels WCJ van de Donk Consulting or advisory role: AbbVie, Adaptive Biotechnologies, Amgen, Bayer, Bristol Myers Squibb/Celgene, Galapagos, Johnson & Johnson, Kite, Merck, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Servier, Takeda Research funding: Amgen, Bristol Myers Squibb/Celgene, Cellectis, Johnson & Johnson, Novartis.
: The CARTITUDE-1, CARTITUDE-2, and CARTITUDE-4 trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. For each trial, the independent ethics committee or institutional review board at each site approved the trial protocol.
